Payment overview · 2025
General Payments
$1,906.06
79 reported records · 17 companies
Healthcare provider profile · identity verified
Hoangvy Le, MD
Allopathic & Osteopathic Physicians|Family Medicine · GARDENA, CA · NPI 1841619095
Verified facts
What the public records show
CMS Open Payments records show Hoangvy Le, MD received $1,906.06 in general payments during 2025 across 79 reported records.
Amgen Inc. accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 257 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Kerendia by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $507.18 | 26.6% | 23 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $257.11 | 13.5% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $198.40 | 10.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $185.41 | 9.7% | 8 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $181.19 | 9.5% | 6 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $98.42 | 5.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $95.04 | 5.0% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $71.57 | 3.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.90 | 3.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.33 | 2.3% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $41.99 | 2.2% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $33.65 | 1.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.11 | 1.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.04 | 1.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $26.48 | 1.4% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.79 | 1.1% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $21.45 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,906.06 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $443.90 | 18 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $443.90 | 18 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $198.40 | 4 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $181.19 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $161.19 | 7 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $130.65 | 6 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $126.46 | 6 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $71.57 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $63.28 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $51.81 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.33 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.45 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.45 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.45 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.23 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.23 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $41.99 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $33.65 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $33.65 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.11 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $28.04 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.04 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $21.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 43 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 60 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 257 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 78 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 106 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
43 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
54 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
257 | 70 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
106 | 29 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
118 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1244 | 360 |
| Amlodipine Besylate | Amlodipine Besylate | 569 | 160 |
| Fluticasone Propionate | Fluticasone Propionate | 420 | 155 |
| Diclofenac Sodium | Diclofenac Sodium | 369 | 168 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 361 | 97 |
| Gabapentin | Gabapentin | 289 | 99 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 266 | 66 |
| Losartan Potassium | Losartan Potassium | 261 | 82 |
| Farxiga | Dapagliflozin Propanediol | 257 | 70 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 250 | 62 |
| Alendronate Sodium | Alendronate Sodium | 245 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 63 |
| Azelastine Hcl | Azelastine Hcl | 220 | 68 |
| Celecoxib | Celecoxib | 202 | 96 |
| Benazepril Hcl | Benazepril Hcl | 200 | 62 |
| Clobetasol Propionate | Clobetasol Propionate | 198 | 74 |
| Metformin Hcl | Metformin Hcl | 184 | 56 |
| Famotidine | Famotidine | 183 | 74 |
| Dexlansoprazole Dr | Dexlansoprazole | 181 | 57 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 180 | 76 |
| Carvedilol | Carvedilol | 152 | 38 |
| Metformin Hcl Er | Metformin Hcl | 150 | 59 |
| Furosemide | Furosemide | 144 | 53 |
| Halobetasol Propionate | Halobetasol Propionate | 142 | 46 |
| Baclofen | Baclofen | 139 | 68 |
| Allopurinol | Allopurinol | 125 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 119 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 43 |
| Atenolol | Atenolol | 118 | 36 |
| Rybelsus | Semaglutide | 118 | 27 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 117 | 30 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 116 | 69 |
| Lisinopril | Lisinopril | 115 | 32 |
| Kerendia | Finerenone | 106 | 29 |
| Meclizine Hcl | Meclizine Hcl | 105 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 26 |
| Valsartan | Valsartan | 100 | 33 |
| Naproxen | Naproxen | 94 | 54 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 93 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 41 |
| Amoxicillin | Amoxicillin | 87 | 72 |
| Mupirocin | Mupirocin | 83 | 36 |
| Omeprazole | Omeprazole | 83 | 31 |
| Vascepa | Icosapent Ethyl | 82 | 20 |
| Finasteride | Finasteride | 81 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 80 | 34 |
| Fluocinonide | Fluocinonide | 80 | 33 |
| Loperamide | Loperamide Hcl | 80 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 23 |
| Jardiance | Empagliflozin | 78 | 21 |
| Ibandronate Sodium | Ibandronate Sodium | 76 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 16 |
| Donepezil Hcl | Donepezil Hcl | 73 | 20 |
| Januvia | Sitagliptin Phosphate | 73 | 17 |
| Dutasteride | Dutasteride | 68 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 16 |
| Azithromycin | Azithromycin | 67 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 20 |
| Ezetimibe | Ezetimibe | 63 | 21 |
| Nifedipine Er | Nifedipine | 62 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 60 | 12 |
| Eliquis | Apixaban | 60 | 17 |
| Montelukast Sodium | Montelukast Sodium | 60 | 23 |
| Colchicine | Colchicine | 58 | 30 |
| Dicyclomine Hcl | Dicyclomine Hcl | 58 | 28 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 56 | 24 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 54 | 19 |
| Zenpep | Lipase/Protease/Amylase | 54 | 19 |
| Mirtazapine | Mirtazapine | 53 | 21 |
| Ibuprofen | Ibuprofen | 52 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 51 | 18 |
| Glipizide Er | Glipizide | 50 | 20 |
| Restasis | Cyclosporine | 49 | 18 |
| Prednisone | Prednisone | 47 | 30 |
| Dapagliflozin | Dapagliflozin Propanediol | 46 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 16 |
| Simvastatin | Simvastatin | 45 | 12 |
| Creon | Lipase/Protease/Amylase | 43 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 42 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 16 |
| Cyclosporine | Cyclosporine | 41 | 21 |
| Entecavir | Entecavir | 40 | suppressed |
| Hydrocortisone | Hydrocortisone | 39 | 11 |
| Tramadol Hcl | Tramadol Hcl | 37 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 36 | 15 |
| Procto-Med Hc | Hydrocortisone | 36 | 18 |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 35 | 15 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 12 |
| Lactulose | Lactulose | 31 | 18 |
| Raloxifene Hcl | Raloxifene Hcl | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 18 |
| Sildenafil Citrate | Sildenafil Citrate | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 25 |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 24 | suppressed |
| Silodosin | Silodosin | 24 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Clotrimazole | Clotrimazole | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 11 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 18 |
| Telmisartan | Telmisartan | 18 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 13 |
| Zafirlukast | Zafirlukast | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Lidocaine | Lidocaine | 15 | suppressed |
| Probenecid | Probenecid | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | 12 |
| Cilostazol | Cilostazol | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | 11 |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 11 | suppressed |
| Zerviate | Cetirizine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,906.06 · 79 records | Amgen Inc. | ABRYSVO, AIRSUPRA, APTIMA, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, FARXIGA, Fluad, Flucelvax, JARDIANCE, KRYSTEXXA, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PYRUKYND, REPATHA, REZDIFFRA, THINPREP 2000 PROCESSOR, VOWST, ZENPEP, ZEPBOUND, ZORYVE, ZTLido | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error